Physician profile
Andy B Carter
NPI 1144451550
$674.25
in general payments reported to CMS, 2019-2025
13 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.84 · 2024: $72.78 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $173.86 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $103.19 | 2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $71.67 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $60.94 | 2025 | Airsupra, Farxiga |
| Viatris Specialty LLC | $57.48 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $45.75 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $39.13 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.23 | 2025 | Caplyta |
| Radius Health, INC. | $29.02 | 2024 | Tymlos |
| Exact Sciences Corporation | $16.85 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.41 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $15.81 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.91 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.